Abstract: A method of making a dosage device comprises mixing a suspension concentrate comprising at least one active ingredient which is in solid form at 25° C., and which has an average particle size of less than 10 microns, in a carrier liquid in which the active ingredient is non-soluble or sparingly soluble, and a drying agent for the carrier liquid. The drying agent takes up at least some of the carrier liquid of the suspension concentrate, thereby to dry the active ingredient at least partly and to obtain a mixture comprising the active ingredient and the drying agent. The mixture is compressed into at least one unitary dosage device.

Abstract: The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.

Abstract: An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, a partial opioid agonist or opioid antagonist is released in a controlled manner over an extended period of time. The composition finds use in the treatment of heroin addicts and alcoholics to reduce consumption of the abused substances. Of particular interest are the drugs buprenorphine, methadone and naltrexone.

Abstract: The invention relates to a pharmaceutical preparation comprising levothyroxine sodium, potassium iodide, microcrystalline cellulose and binding agent, which is free of antioxidants or further auxiliaries, and processes for its production.

Abstract: A process for preparing free-flowing and, during handling, dust-free microparticles. The particles are at least 90% by weight, have a diameter of 100-400 &mgr;m, and contain one or more active ingredients in a glassy matrix. Generally, the process of the invention comprises the steps of (1) preparing an aqueous solution of the matrix materials, (2) mixing the flavor into the aqueous solution with stirring to form an emulsion or suspension, (3) spraying the emulsion in a spray drying tower under a supply of hot air to quickly create a semi-solid skin allowing outtake of moisture (water), and (4) subsequently subjecting the resulting particles to continued drying at lower temperatures in a fluid bed.

Abstract: A synthetic particulate vector comprising a non-liquid hydrophilic nucleus which does not have an external lipid layer grafted thereon. A method for preparing a particulate vector by encapsulating an ionizable active principle, vectors obtainable through said method, and pharmaceutical, cosmetological or food compositions containing such vectors are also disclosed.

Abstract: An anhydrous skin treatment composition is provided which includes a crosslinked siloxane elastomer gel of specific yield point, a skin conditioning agent and a volatile siloxane. Inclusions of the select elastomers provide improved uniform distribution of the pigments.

Abstract: A powder for use in a dry powder inhaler comprises active material and additive material. The additive material comprises an anti-adherent material and the powder includes at least 60% by weight of active material. The inclusion of the additive material in the powder has been found to give an increased respirable fraction of the active material.

Abstract: A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose.

Abstract: The invention provides finely divided, substantially crystalline particles of budesonide characterized in that they are substantially smooth and having a BET value of from 1 to 4.5 m2/g, a process for their preparation, a pharmaceutical composition comprising said particles, the use of said particles in the treatment of and in the manufacture of a medicament for use in the treatment of respiratory disorder, and a method of treatment of respiratory disorders by administration of said particles to a host in need of such treatment.

Abstract: The invention provides a process for preparing essentially crystalline particles containing a substance in solvated form, by dissolving the substance in a first solvent, introducing the solution and a supercritical or subcritical fluid into an apparatus, wherein the fluid contains an anti-solvent and a second solvent, which is water. Preferably, the anti-solvent is carbon dioxide which is totally saturated with the second solvent, which is water. The invention further provides formulations comprising particles produced according to the present process containing one or more pharmacologically active substances and one or more pharmaceu-tically acceptable excipients, use of said formulations in the treatment of an allergic and/or inflammatory condition of the nose or lungs and methods for treatment of such conditions.

Abstract: A cosmetic consists of a cosmetic raw material in the form of an emulsion of silicone or organic oil containing crosslinked particles mixed with other cosmetic raw materials. Its touch on fingers and skin is good, spreading and feel during use are good, and it can also prevent unruly hair, stray hair, and tangling of hair, so hair can easily be arranged. It imparts a fresh, dry feeling without any stickiness. The cosmetic raw material consists of the silicone or organic oil emulsion containing crosslinked particles with a mean particle diameter of 0.05 to 100 &mgr;m. Crosslinking is obtained by an hydrosilylation of liquid crosslinkable compositions consisting of (A) organic compounds with at least two aliphatic unsaturated bonds per molecule, (B) silicon containing organic compounds with at least two hydrogen atoms bonded to silicon atoms in each molecule, and (C) hydrosilylation reaction catalysts.

Abstract: The present invention relates to a mixture of a starch and at least one other excipient for tabletting wherein the starch is free-flowing compressible processed starch powder suitable for use both as a binder and as a disintegrant in tablets. The free-flowing starch powder improves the characteristics and the properties of the tablets when mixed with one or more different excipients. The present invention also discloses a method for obtaining tablets comprising the free-flowing compressible processed starch together with at least one excipient and the tablets obtained by such a method.

Abstract: Disclosed are cosmetic compositions including lipsticks, comprising from about 0.01% to about 50%, by weight, of a crystalline vitamin B3 compound having an average particle size of from about 0.01 &mgr;m to about 200 &mgr;m; from about 1% to about 90%, by weight, of an emollient component; and from about 1% to about 90%, by weight, of a solidifying agent. The compositions provide improved skin feel of crystalline vitamin B3 compounds when applied to skin.

Abstract: A cosmetic composition is provided which includes at least about 2% solid asymmetric particles, a retinoid solubilized in a fluid oil and wherein the fluid oil to solid particles are present in a weight ratio such that the composition exhibits a normal force value of less than −100 milli-Newton containing a retinoid. The composition diminishes the appearance and feel of oily skin and is capable of delivering benefits associated with retinoids.

Abstract: Particles of a substantially water insoluble biologically active substance, such as Cyclosporin, are loaded with a charged glyceryl ester as an electrostatic stabilizer which imparts to the particles a zeta potential and having an active substance:stabilizer weight ratio of 1:1 to 400:1 and an average particle diameter of 1 nanometer to 10 micrometers. Compositions having such particles are found to be useful delivery systems.

Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.

Abstract: Agglomerates of &bgr;-lactam antibiotics, such as penicilllin V potassium, amoxicillin trihydrate, cephalexin monohydrate, which are suitable for direct tablet formation.

Abstract: Disclosed is an evacuant possessing a sufficient evacuating effect in a small dose substantially without accompanying any irritation to bowel, irrespective of whether its preparations are in the form of tablets, liquids or elixirs, and having a suppressing action to odor of feces. This evacuant is characterized by containing an active magnesium oxide which has a BET value (surface area in terms of m2/g) of at least 21, preferably 21-50, more preferably 30-40 and is excellent in acid reactivity, and may preferably be incorporated with lactic acid bacteria, a mixture of sporolactobacteria and yeast extracts and/or oligosaccharides. The preparations are preferably in the form of liquids, granules, tablets and capsules.

Abstract: A multiple unit oral pharmaceutical dosage form having a plurality of pellets in a water soluble capsule or in a tablet compressed from the pellets, wherein each pellet contains (a) a substantially inert core, (b) an active ingredient layer over the inert core, and containing (i) a pharmacologically active particulate active ingredient, (ii) a nonembedding amount of a binder for adhering the active ingredient over the inert core, and optionally (iii) a pharmaceutically acceptable, inert adjuvant, such as colloidal silica, and (c) a coating over the active ingredient layer for retarding the release of the active ingredient from the active ingredient layer into an aqueous body fluid solvent in situ, the nonembedding amount of the binder is suitably from about 1% wt. to about 10% wt.

Abstract: A deodorant composition with active antibacterial constituents comprising on a weight basis the plant extracts of Myrtus from about 2% to about 8%, Laurus nobilis, from about 1% to 5% Drosera extract from about 1% to 7%, Myrrhis resin from about 3% to about 6%, and water 74% to 93%. Preferably, the composition is free of alcohol and aluminum.

Abstract: The effervescent granules with delayed effervescent effect consist of at least one acid component and one component evolving gas under the action of acid, as well as of active substances, fragrances, plant extracts, vitamins, minerals etc. admixed as needed, the particles of the acid component being coated with—preferably 1 to 30% by weight of—at least one carbonate compound—possibly including a partial reaction—and/or a hydrocolloid. The gas-evolving component consists of alkali hydrogen carbonate, alkali carbonate, and/or alkaline-earth carbonate particles which are coated with at least one further substance, particularly with a melt of polyethylene glycol 6000. The particles preferably have a grain size above 0.2 mm.

Abstract: Improved powder coatings exhibit enhanced resistance to bacterial and fungal attack, while possessing excellent toughness, appearance, corrosion resistance, durability, processability, and ease of application. The coating is comprised of anti-microbial agents melt-processed into the matrices of coating powders or bonded to coating powders. An article may be coated with a thermoset or thermoplastic powder that may be applied by electrostatic spray or fluidized bed or by thermal or flame spray.

Abstract: Pyrogenically prepared silica doped with silver or silver oxide is prepared by feeding an aerosol into a flame such as is used for the preparation of pyrogenic silica, mixing the aerosol homogeneously with gas mixture before the reaction, then allowing the aerosol/gas mixture to react in a flame. The resulting pyrogenic silicas doped with silver or silver oxide are separated from the gas stream. The pyrogenic silica doped with silver or silver oxide by means of an aerosol can be used as a bactericidal filler.

Abstract: This invention relates to a method for treating inflammatory symptoms such as burning, redness, itching, swelling and pain which accompany skin disorders other than wounds of the skin. The method comprising topical application of a topical medicinal composition comprising a non-interlinked, particulate bioactive glass mixed with a topical medicinal carrier to the site of the skin disorder.

Abstract: A pharmaceutical composition in the form of an emulsion preconcentrate for oral administration and containing a cyclosporin. The pharmaceutical composition has a carrier medium for the cyclosporin that contains a hydrophilic organic solvent; a mixed mono-, di-, and tri-glyceride or a transesterified and polyethoxylated vegetable oil; and a polyoxyethylene-sorbitan-fatty acid ester surfactant. The pharmaceutical composition provides high bioavailability and low inter- and intra-subject variability.

Abstract: An improved termite bait composition comprises a powdered cellulosic attractant having a particle size in the range of approximately 1 to 100 micrometers and a termite killing agent. Also disclosed are a method for controlling termites by applying the termite bait composition to a termite infested area and a termite bait composition package for use in a termite bait station comprising the termite bait composition contained within a termite attractive package.

Abstract: A termiticide which comprises at least one compound which in the presence of a termite produces a termiticidally effective amount of hydrogen sulfide.

Abstract: This invention relates to novel, liquid crystal forms of the cyclic peptide cyclosporin and to novel powder formulations of cyclosporin prepared using this novel liquid crystal form of the drug. Methods for preparing and using these formulations are also provided. In particular, the present invention relates to dispersible spray dried particles of cyclosporin suitable for pulmonary delivery.

Abstract: Injectable activated carbon suspensions are proposed for the presurgical marking of nonpalpable mammary pathologies for the purpose of achieving better diagnosis and treatment. These are suspensions that flow freely and without the formation of obstructing aggregates in the needles used during their application, with carbon particles of micron granulometry limited to less than 50&mgr; and preferably between 2&mgr; and 6&mgr; in concentration of approximately 4.0% p/v in saline aqueous medium. A process is also proposed for preparing said compositions.

Abstract: A high speed agitation granulator method of preparing a substantially spherical granule for pharmaceutical use comprising a medicament for pharmaceutical use, wherein the medicament has an aqueous solubility of 0.01 to 0.30 g/ml, which method comprises introducing a mixture of medicament and excipients comprising at least 5% crystalline cellulose into the granulator and spraying on water or a mixture of ethanol and water as binder solution; a substantially spherical granule for pharmaceutical use comprising famciclovir and 5% or more crystalline cellulose, together with an optional coating; and a sachet containing a unit dose of famciclovir in the form of such granules.

Abstract: The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.

Abstract: There is described a solid particulate pharmaceutical formulation suitable for application to the nose comprising finely divided additive particles and finely divided drug particles, wherein the mass median diameter of the drug particles is greater than that of the additive particles.

Abstract: The present invention relates to multi-unitary pharmaceutical preparations containing piroxicam for oral administration. Such pharmaceutical preparations are stable pellet pharmaceutical preparations containing piroxicam and they comprise an amount of active ingredient of between 5 and 50 mg, an inert core with spherical symmetry and a diameter of 600-850 &mgr;m, constituted by inert excipients, coated with an active layer containing piroxicam in micronized form and various pharmaceutically acceptable inert excipients, mixed in appropriate proportions in order to allow the adequate disaggregation of the formulations and dissolution of the active ingredient, coated in it turn with an insulating layer of a polymeric nature and soluble in water, this layer being coated finally with a gastroresistant or enteric layer of a minimum thickness of 20 &mgr;m. This invention also refers to the process for the preparation of said pharmaceutical preparations.

Abstract: The invention provides a particle comprising fibrinogen bound on the surface of an albumin matrix, wherein said particle is capable of coaggregation with platelet, and of aggregation in a solution containing soluble fibrinogen at a concentration of soluble fibrinogen not capable by it self of formation of a clot upon activation by thrombin.

Abstract: A storage stable magnesium oxychloride coated granular animal feed mineral supplement composition resistant to disintegration cause by moisture absorption and attrition, comprising granular mineral nutrients useful as animal feed supplements and magnesium oxychloride coatings amounting to between 0.5 and 10.0 percent of the weight of the granules, formed on the granules of mineral nutrients by coreaction of magnesium chloride and magnesium oxide. An additional coating of between 0.2 and 2.0 percent magnesium stearate formed on the magnesium oxychloride may be used to decrease the rate of wetting of the granular animal feed mineral supplements.

Abstract: A method for preparing sterol/stanol and sterol/stanol ester compositions with improved dispersibility is provided by co-melting the sterol/stanol and/or sterol/stanol ester with highly branched hydrocarbons and then grinding the resulting product. A method for preparing the compounds is also disclosed. The ground compound is suitable for formulating into orally administered products suitable for control of blood serum cholesterol.

Abstract: A crystalline bulk powder of N-(1-((2,4-diamino-6-pteridinyl)methyl)-3,4-dihydro-2H-1,4-benzothiazine-7-carbonyl)L-&agr;-aminoadipic acid is treated by using an impact grinding method or a jet mill grinding method to give a finely ground powder. Solid oral preparations containing the thus obtained finely ground powder as the active ingredient can quickly release the active ingredient and high content uniformity can be ensured without adversely affecting the stability.

Abstract: A pharmaceutical formulation may be prepared by a method comprising providing the active ingredient in solution in a pharmacologically-acceptable base and mixing the resulting solution with a pharmacologically-acceptable acid in an amount such that the formulation attains a pH in the range of from about 3.5 to about 8.5 to thereby precipitate out the active ingredients, a viscosity-enhancing agent having been incorporated in the formulation prior to or during the mixing with acid. The formulation is suitable for administration of a pharmacologically active ingredient which is sparingly soluble in water at a pH acceptable for administration, for example to the eye of the patient.

Abstract: Agrochemical granulated material which is dispersible in water and contains a mixture that is liquid, gel-like, or waxy at +25° C., comprising at least one agrochemical active ingredient and at least one surface-active compound and a thickening agent, and optionally having an outer coating, characterized in that the granulated material has plastic behavior at +25° C.

Abstract: The present invention provides a sterol, stanol or their corresponding acid ester in a form suitable for the manufacture of an oral dosage form. A method for producing the oral dosage form is also provided.

Abstract: Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for making and using the compositions are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth.

Abstract: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (iii) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively hi

Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble &bgr;-glucan composition comprising &bgr;-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).

Abstract: A dry powder formulation for treatment of pulmonary conditions, via inhalation, includes an effective amount of formoterol or a salt or solvate thereof, in a dry powder form, an effective amount of fluticasone, in a dry powder form, and an excipient. A method for preparing a physically stable dry powder formulation for inhalation includes the steps of micronizing a first active polar drug, a second active non-polar drug, and a polar excipient. The second non-polar active drug is first blended with the excipient to form an intermediate mixture. The intermediate mixture is then blended with the first active polar drug. The increased separation of the polar drug and polar excipient stabilizes the formulation.

Abstract: A novel encapsulated product is provided and includes: at least one active ingredient; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. The encapsulated product may be incorporated into a food item, a soft confectionery product, a hard confectionery product, a jelly gum confectionery product, and a dry beverage or chewing gum product.

Abstract: The invention provides finely divided, substantially crystalline particles of budesonide characterised in that they are substantially smooth and having a BET value from 1 to 4.5 m2/g, process for their preparation, a pharmaceutical composition comprising said particles, the use of said particles in the treatment of and in the manufacture of a medicament for use in the treatment of a respiratory disorder, and a method of treatment of respiratory disorders by administration, to a host in need of such treatment, said particles.

Abstract: Dispersibility of a respirable powder, administrable by inhalation, is increased by including a pharmaceutically acceptable water-soluble polypeptide.

Abstract: Piece-form materials which comprise 5-100% by mass calcium formate and 95-0% by mass additives and have particle sizes of 0.2-5 mm can be prepared from finely crystalline calcium formate and the additives by compression and, if necessary, subsequent comminution and/or fractionation to set the particle size.

Abstract: The invention provides finely divided, substantially crystalline particles of budesonide characterized in that they are substantially smooth and having a BET value from 1 to 4.5 m2/g, process for their preparation, a pharmaceutical composition comprising said particles, the use of said particles in the treatment of and in the manufacture of a medicament for use in the treatment of a respiratory disorder, and a method of treatment of respiratory disorders by administration of said particles to a host in need of such treatment.